EudraCT Number: 2021-006709-31 Sponsor Protocol Number: COAV101B12302 Start Date: 2022-08-12
Sponsor Name: Novartis Pharma AG
Full Title: Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101 administered intrathecally (1.2 x 1014 vector genomes) to participants 2 to 12 yea...
Medical condition: Spinal Muscular Atrophy
Disease: Version SOC Term Classification Code Term Level
20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-006868-24 Sponsor Protocol Number: UMCN-AKF-21.05 Start Date: 2022-08-02
Sponsor Name: Radboud university medical centre
Full Title: Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS)
Medical condition: Invasive fungal disease
Disease: Version SOC Term Classification Code Term Level
20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002639-48 Sponsor Protocol Number: 54767414AMY2009 Start Date: 2022-07-25
Sponsor Name: Janssen-Cilag International N.V.
Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
Medical condition: Amyloid Light Chain Amyloidosis
Disease: Version SOC Term Classification Code Term Level
23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) IT (Ongoing) NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000049-34 Sponsor Protocol Number: ACT16753 Start Date: 2022-07-21
Sponsor Name: Sanofi-aventis recherche & développement
Full Title: A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long...
Medical condition: Multiple sclerosis
Disease: Version SOC Term Classification Code Term Level
20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-003664-28 Sponsor Protocol Number: Cp50PropofolPregabalin Start Date: 2022-07-18
Sponsor Name: Medical University of Vienna, Department of Anaesthesia, Critical Care and Pain Medicine
Full Title: The Effect of Pregabalin on the Cp50 of Propofol
Medical condition: This study aims to investigate the effect of a clinically used dose of Pregabalin on the Cp50 of propofol to provide more information to clinicians using this adjunctive drug in the perioperative s...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003669-36 Sponsor Protocol Number: MS100070_0119 Start Date: 2022-07-14
Sponsor Name: Merck Healthcare KGaA
Full Title: A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with L...
Medical condition: Advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy.
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
Population Age: Adults Gender: Male, Female
Trial protocol: ES (Ongoing) DK (Ongoing) GR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002163-22 Sponsor Protocol Number: NANORAY-312 Start Date: 2022-07-13
Sponsor Name: Nanobiotix SA
Full Title: A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for platinum-based Chemotherapy-ineligible Elderly P...
Medical condition: Locally Advanced Head & Neck Squamous Cell Carcinoma
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
Population Age: Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-002344-73 Sponsor Protocol Number: LTS17367(KY1005-CT06) Start Date: 2022-07-12
Sponsor Name: Sanofi-aventis recherche & développement
Full Title: A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis who participated ...
Medical condition: Dermatitis atopic
Disease: Version SOC Term Classification Code Term Level
20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HU (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-004676-18 Sponsor Protocol Number: 213340 Start Date: 2022-07-07
Sponsor Name: University Medical Center Utrecht
Full Title: Differences in effect of treatment with mepolizumab and benralizumab on resident and inflammatory eosinophils
Medical condition: severe eosinophilic asthma
Disease: Version SOC Term Classification Code Term Level
20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
Population Age: Adults Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-000857-23 Sponsor Protocol Number: D7020C00001 Start Date: 2022-07-06
Sponsor Name: AstraZeneca AB
Full Title: A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Pa...
Medical condition: Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer, stage IV Non-small Cell Lung Cancer.
Disease: Version SOC Term Classification Code Term Level
20.1 100000004864 10080083 Advanced lung cancer LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing) BE (Ongoing) NL (Ongoing) ES (Ongoing)
Trial results: (No results available)